First AD

Second AD

Considerations for Third-Line Treatment in Chronic GVHD

Video content above is prompted by the following:

 For patients showing inadequate response to second-line therapies, what factors guide your treatment selection in third line and beyond?

Please discuss the role of safety concerns, organ involvement, severity, etc, in your decision to use one agent over another.

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

My Treatment Approach: Optimizing Treatment for Chronic GVHD

Medical experts discuss considerations for third-line treatment in chronic GVHD. 